SCHEMBL21484879

SCHEMBL21484879

N#CCC(=O)Nc1nc(-c2ccccc2)c(C2CCOCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 1/20 0.49
TRPV4 Q9HBA0 1/20 0.46
ALDH1A1 P00352 7/20 0.46
HSD17B10 Q99714 2/20 0.41
MAPK1 P28482 1/20 0.41
ADORA2A P29274 6/20 0.41
ADORA1 P30542 5/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TSHR P16473 2/20 0.41
CLK1 P49759 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
USP30 Q70CQ3 3/20 0.40
CASR P41180 1/20 0.40
HPGD P15428 1/20 0.40
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484639 0.89 MRE11 (0.59) MRE11TRPV4ALDH1A1HSD17B10MAPK1
SCHEMBL21484729 0.77 PTGS2 (0.58) MRE11ALDH1A1HSD17B10MAPK1ADORA2A
SCHEMBL21505993 0.76 ALDH1A1 (0.48) ALDH1A1HSD17B10MAPK1ADORA2AADORA1
SCHEMBL21484846 0.76 ALDH1A1 (0.67) ALDH1A1HSD17B10MAPK1NPC1RAB9A
SCHEMBL21484782 0.76 ALDH1A1 (0.49) MRE11ALDH1A1HSD17B10MAPK1ADORA2A
SCHEMBL21484898 0.76 ALDH1A1 (0.48) ALDH1A1HSD17B10MAPK1ADORA2AADORA1
SCHEMBL21484865 0.75 MRE11 (0.46) MRE11TRPV4ALDH1A1KDM4EMAPT
SCHEMBL21484758 0.74 EGFR (0.52) MRE11ALDH1A1HSD17B10MAPK1RAB9A
SCHEMBL21484599 0.72 SMN1; SMN2 (0.58) MRE11ALDH1A1HSD17B10MAPK1ADORA2A
SCHEMBL2789732 0.71 ACP1 (0.67) ALDH1A1HSD17B10MAPK1ADORA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MRE11 68/4885TRPV4 4848/4885ALDH1A1 2267/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MRE11 68/4885TRPV4 4848/4885ALDH1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.